Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Austin Lui, Jordan Vanleuven, David Perekopskiy, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1546-1546
Open Access | Times Cited: 16

Showing 16 citing articles:

Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA
Abigail Brewer, Gajanan Sathe, Billie E. Pflug, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109302-109302
Open Access | Times Cited: 8
Unlocking the therapeutic potential of protein kinase inhibitors in neurodegenerative and psychiatric disorders
A. V., Polina Buzaeva, Izhak Michaelevski
(2025) Vol. 2, Iss. 6
Open Access | Times Cited: 1
Uncovering Cell Cycle Dysregulations and Associated Mechanisms in Cancer and Neurodegenerative Disorders: A Glimpse of Hope for Repurposed Drugs
Dia Advani, Pravir Kumar
Molecular Neurobiology (2024)
Closed Access | Times Cited: 4
Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders
Austin Lui, Timothy Do, Omar Alzayat, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 426-426
Open Access | Times Cited: 3
PROTAC chemical probes for histone deacetylase enzymes
Urvashi Patel, Joshua P. Smalley, James T. Hodgkinson
RSC Chemical Biology (2023) Vol. 4, Iss. 9, pp. 623-634
Open Access | Times Cited: 9
Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation
Vanesa Nozal, Paula Fernández-Gómez, Alfonso Garcı́a-Rubia, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116626-116626
Open Access | Times Cited: 2
Developing theragnostics for Alzheimer's disease: Insights from cancer treatment
Hyunju Lee, Hee-Jeong Choi, Yoo Joo Jeong, et al.
International Journal of Biological Macromolecules (2024) Vol. 269, pp. 131925-131925
Open Access | Times Cited: 2
MicroRNA-based interventions in aberrant cell cycle diseases: Therapeutic strategies for cancers, central nervous system disorders and comorbidities
Xiaojuan Tang, Yuan Ren, Wen Zeng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116979-116979
Open Access | Times Cited: 2
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome
Laurent Meijer, Emilie Chrétien, Denis Ravel
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S95-S113
Closed Access | Times Cited: 2
Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD
Hyunju Lee, Jeong-Woo Hwang, Jin-Hee Park, et al.
Molecular Brain (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Application of parallel artificial membrane permeability assay technique and chemometric modeling for blood–brain barrier permeability prediction of protein kinase inhibitors
Milan Jovanović, Milica Radan, Marija Čarapić, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 9, pp. 873-885
Open Access | Times Cited: 1
Comparative Docking Strategies for Alzheimer’s Therapy: Exploring Drug and Phytocompound Interactions with BIN1 Protein
Ashima Gulia, Pravir Kumar
(2024), pp. 1895-1899
Closed Access
Serum/glucocorticoid regulated kinase 1 (SGK1) in neurological disorders: Pain or gain
Peyton Grace Howard, Peibin Zou, Yulan Zhang, et al.
Experimental Neurology (2024) Vol. 382, pp. 114973-114973
Closed Access
FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
Dezhu Gao, Yu Shi, Zhiliang Wang, et al.
(2024) Vol. 2, Iss. 6, pp. 851-866
Open Access
Immunotherapy for Neurodegenerative Movement Disorders
R. Lee Mosley, Maamoon Saleh, Katherine E. Olson
NeuroImmune Pharmacology and Therapeutics (2024), pp. 943-973
Closed Access
Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA
Abigail Brewer, Gajanan Sathe, Billie E. Pflug, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top